Clinical Efficacy of Acupuncture and Paraffin Wax Therapy in the Treatment of Carpal Tunnel Syndrome
NCT07932548, Phase 2, Phase 3, Not yet recruiting, The University of Health Sciences, VNU-HCM
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Clinical Efficacy of Acupuncture and Paraffin Wax Therapy in the Treatment of Carpal Tunnel Syndrome | ClinicalTrials.gov |
| NCT number | NCT07932548 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Phase 2, Phase 3 | ClinicalTrials.gov |
| Enrollment | 177 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | The University of Health Sciences, VNU-HCM | ClinicalTrials.gov |
| Conditions | Carpal Tunnel Syndrome (CTS) | ClinicalTrials.gov |
| Interventions | Electroapuncture and paraffin wax therapy, Electropuncture, Paraffin wax therapy | ClinicalTrials.gov |
| First posted | 2026-11-12 | ClinicalTrials.gov |
| Last updated | 2026-11-12 | ClinicalTrials.gov |
Registered outcomes 5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Boston Carpal Tunnel Questionnaire's symptom severity scale | Baseline (pre-intervention) and after 3 weeks | This questionnaire includes 11 items assessing symptom severity, each scored on a 5-point scale from 1 (mildest) to 5 (most severe). Total raw score from 11 to 55, final score 1 to 5 (Final score = Raw score / 11). Higher score means greater symptom severity and worse impairment. A score of 1 indicates no symptoms, while a score of 5 indicates severe, constant symptoms. | ClinicalTrials.gov |
| Primary | Functional Status Scale - BCTQ-FSS | Baseline (pre-intervention) and after 3 weeks | This questionnaire includes 8 items assessing function. Each question score from 1 to 5 (1 = No difficulty, 5 = Cannot perform at all due to symptoms) Total raw score is from 8 to 40. Final score is 1 to 5 (Final score = raw score / 8). Higher score means greater functional disability and impairment. A score of 1.0 represents normal hand function, while 5.0 represents complete inability to perform basic tasks. | ClinicalTrials.gov |
| Secondary | Phalen, Tinel test | Baseline (pre-intervention) and after 3 weeks | Phalen's Test: Positive if tingling, numbness, or pain in the median nerve distribution is reproduced or worsened within 60 seconds of maximal wrist flexion. Tinel's Sign: Positive if tapping directly over the median nerve at the flexor retinaculum of the wrist elicits a sensation of tingling or an electric shock-like feeling radiating into the fingers. | ClinicalTrials.gov |
| Secondary | Muscle strength assessment | Baseline (pre-intervention) and after 3 weeks | Arm Muscle strength assessment, scale from 0 to 5. High Score (Grade 5): Normal muscle strength. The muscle can move the joint through its full range of motion against strong manual resistance applied by the examiner. Low Score (Grade 0): Complete paralysis. No visible muscle contraction or movement occurs. | ClinicalTrials.gov |
| Secondary | Side effects | periprocedurally | Unwanted side effects (or adverse events) of electroacupuncture, paraffin wax bath, and the combination of electroacupuncture and paraffin wax bath during the study period. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 10
The papers the trial lists on ClinicalTrials.gov.
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)